|
KR101483215B1
(ko)
*
|
2010-01-29 |
2015-01-16 |
한미약품 주식회사 |
단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
|
|
RU2604062C2
(ru)
|
2010-07-13 |
2016-12-10 |
Ф.Хоффманн-Ля Рош Аг |
ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4
|
|
EP3239154A1
(en)
|
2011-01-10 |
2017-11-01 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
WO2012129258A1
(en)
|
2011-03-22 |
2012-09-27 |
Merck Sharp & Dohme Corp. |
Amidopyrazole inhibitors of interleukin receptor-associated kinases
|
|
EP2723746A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
RU2625799C2
(ru)
*
|
2011-12-30 |
2017-07-19 |
Ханми Фарм. Ко., Лтд. |
ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ
|
|
BR112014017021A8
(pt)
|
2012-01-10 |
2017-07-04 |
Nimbus Iris Inc |
inibidores de irak e usos dos mesmos
|
|
RU2637925C2
(ru)
|
2012-01-10 |
2017-12-08 |
Ф. Хоффманн-Ля Рош Аг |
Соединения тиенопиримидина
|
|
WO2014003483A1
(en)
*
|
2012-06-29 |
2014-01-03 |
Hanmi Pharm. Co., Ltd. |
Fused pyrimidine derivatives having inhibitory activity on fms kinases
|
|
CA2878621C
(en)
*
|
2012-07-10 |
2020-09-15 |
Ares Trading S.A. |
Pyrimidine pyrazolyl derivatives
|
|
WO2014011911A2
(en)
*
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
US9085586B2
(en)
|
2012-07-11 |
2015-07-21 |
Nimbus Iris, Inc. |
IRAK inhibitors and uses thereof
|
|
WO2014011906A2
(en)
*
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
LT3486245T
(lt)
|
2012-12-07 |
2021-08-25 |
Vertex Pharmaceuticals Incorporated |
2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamidas, kaip atr kinazės inhibitorius
|
|
WO2014110114A1
(en)
|
2013-01-10 |
2014-07-17 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
US9278950B2
(en)
|
2013-01-14 |
2016-03-08 |
Incyte Corporation |
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
|
|
AU2014207691B2
(en)
|
2013-01-15 |
2018-08-30 |
Incyte Holdings Corporation |
Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
|
|
US8778365B1
(en)
|
2013-01-31 |
2014-07-15 |
Merz Pharmaceuticals, Llc |
Topical compositions and methods for making and using same
|
|
EP2970288A1
(en)
*
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2014143241A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
JP2016512815A
(ja)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
EP3019171B1
(en)
*
|
2013-07-11 |
2018-09-05 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
|
WO2015027124A1
(en)
|
2013-08-23 |
2015-02-26 |
Incyte Corporation |
Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
|
|
BR112016006319A2
(pt)
|
2013-09-27 |
2017-08-01 |
Nimbus Iris Inc |
inibidores de irak e usos dos mesmos
|
|
CA2932757C
(en)
|
2013-12-06 |
2023-10-31 |
Vertex Pharmaceuticals Incorporated |
2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
|
|
US9908872B2
(en)
|
2013-12-13 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
JP6879740B2
(ja)
|
2013-12-13 |
2021-06-02 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
リンパ形質細胞性リンパ腫を処置する方法
|
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
MX2016009011A
(es)
|
2014-01-10 |
2017-01-23 |
Aurigene Discovery Tech Ltd |
Compuestos de indazol como inhibidores de cinasa-4 asociada al receptor de interleucina-1 (irak4).
|
|
HRP20181795T1
(hr)
|
2014-01-13 |
2019-01-25 |
Aurigene Discovery Technologies Limited |
Biciklički heterociklilni derivati kao inhibitori irak4
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
KR20170005870A
(ko)
*
|
2014-05-23 |
2017-01-16 |
에프. 호프만-라 로슈 아게 |
Jak 억제제인 5-클로로-2-다이플루오로메톡시페닐 피라졸로피리미딘 화합물
|
|
AU2015271030B2
(en)
|
2014-06-05 |
2019-05-16 |
Vertex Pharmaceuticals Incorporated |
Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof
|
|
LT3157566T
(lt)
|
2014-06-17 |
2019-08-12 |
Vertex Pharmaceuticals Incorporated |
Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
|
|
WO2016010897A1
(en)
|
2014-07-14 |
2016-01-21 |
Incyte Corporation |
Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
|
|
US9580418B2
(en)
|
2014-07-14 |
2017-02-28 |
Incyte Corporation |
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
|
|
US10112957B2
(en)
|
2014-10-22 |
2018-10-30 |
Dana-Farber Cancer Institute, Inc. |
Thiazolyl-containing compounds for treating proliferative diseases
|
|
CA2966581A1
(en)
|
2014-11-06 |
2016-05-12 |
Lysosomal Therapeutics Inc. |
Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
|
|
IL252053B2
(en)
|
2014-11-06 |
2024-04-01 |
Lysosomal Therapeutics Inc |
SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
|
|
US20170333435A1
(en)
|
2014-11-06 |
2017-11-23 |
Lysosomal Therapeutics Inc. |
Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
|
|
HUE047586T2
(hu)
*
|
2014-11-20 |
2020-04-28 |
Merck Patent Gmbh |
Heteroaril vegyületek mint IRAK inhibitorok és alkalmazásaik
|
|
EP3267996B1
(en)
*
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of irak4 activity
|
|
WO2016144848A1
(en)
*
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrrolotriazine inhibitors of irak4 activity
|
|
EP3268004B1
(en)
|
2015-03-12 |
2019-12-18 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of irak4 activity
|
|
WO2016144849A1
(en)
*
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of irak4 activity
|
|
US10155765B2
(en)
|
2015-03-12 |
2018-12-18 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of IRAK4 activity
|
|
WO2016196244A1
(en)
|
2015-05-29 |
2016-12-08 |
Incyte Corporation |
Pyridineamine compounds useful as pim kinase inhibitors
|
|
WO2017004134A1
(en)
*
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
HK1249509A1
(zh)
*
|
2015-07-15 |
2018-11-02 |
Aurigene Discovery Technologies Limited |
作为irak-4抑制剂的吲唑及氮杂吲唑化合物
|
|
AR105967A1
(es)
|
2015-09-09 |
2017-11-29 |
Incyte Corp |
Sales de un inhibidor de pim quinasa
|
|
WO2017049206A1
(en)
|
2015-09-17 |
2017-03-23 |
City Of Hope |
Pcna inhibitors
|
|
CN105237414B
(zh)
*
|
2015-09-30 |
2017-03-22 |
浙江永宁药业股份有限公司 |
ivacaftor中间体及其制备方法和用途
|
|
WO2017059357A1
(en)
|
2015-09-30 |
2017-04-06 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of dna damaging agents and atr inhibitors
|
|
WO2017059251A1
(en)
|
2015-10-02 |
2017-04-06 |
Incyte Corporation |
Heterocyclic compounds useful as pim kinase inhibitors
|
|
WO2017108723A2
(en)
*
|
2015-12-22 |
2017-06-29 |
F. Hoffmann-La Roche Ag |
PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
|
|
EP3440081A4
(en)
|
2016-04-06 |
2019-09-18 |
Lysosomal Therapeutics Inc. |
PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
|
|
MX2018012211A
(es)
|
2016-04-06 |
2019-03-28 |
Lysosomal Therapeutics Inc |
Compuestos de pirazol[1,5-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
|
|
CA3020305A1
(en)
|
2016-04-06 |
2017-10-12 |
Lysosomal Therapeutics Inc. |
Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
WO2017192841A1
(en)
*
|
2016-05-04 |
2017-11-09 |
Lysosomal Therapeutics Inc. |
Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
|
|
WO2017192931A1
(en)
|
2016-05-05 |
2017-11-09 |
Lysosomal Therapeutics Inc. |
SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
|
|
EP3452481A4
(en)
|
2016-05-05 |
2020-02-26 |
Lysosomal Therapeutics Inc. |
IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS
|
|
CN106222183B
(zh)
*
|
2016-07-25 |
2019-11-08 |
南通大学 |
靶向人irak1基因的小干扰rna及其应用
|
|
CN109890829B
(zh)
*
|
2016-11-02 |
2022-07-15 |
豪夫迈·罗氏有限公司 |
作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
|
|
IL268128B2
(en)
*
|
2017-02-01 |
2023-03-01 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
n1-(4-(5-(cyclopropylmethyl)-1-methyl-1-h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or Iraki inhibitors for cancer therapy
|
|
JOP20180011A1
(ar)
|
2017-02-16 |
2019-01-30 |
Gilead Sciences Inc |
مشتقات بيرولو [1، 2-b]بيريدازين
|
|
IL269536B
(en)
|
2017-03-31 |
2022-07-01 |
Aurigene Discovery Tech Ltd |
Compounds and preparations for the treatment of hematological disorders
|
|
CN106946890A
(zh)
*
|
2017-04-26 |
2017-07-14 |
中国药科大学 |
吡啶类irak4抑制剂、其制备方法及应用
|
|
WO2018215389A1
(en)
|
2017-05-22 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Therapeutic compounds and compositions, and methods of use thereof
|
|
WO2018234343A1
(en)
*
|
2017-06-21 |
2018-12-27 |
F. Hoffmann-La Roche Ag |
BENZOFURANES AS MODULATORS OF IRAQ4
|
|
WO2018234342A1
(en)
*
|
2017-06-21 |
2018-12-27 |
F. Hoffmann-La Roche Ag |
ISOINDOLINONE DERIVATIVES AS MODULATORS OF IRAK4
|
|
EP3642204A1
(en)
|
2017-06-21 |
2020-04-29 |
H. Hoffnabb-La Roche Ag |
PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
|
|
WO2019001460A1
(zh)
*
|
2017-06-27 |
2019-01-03 |
南京明德新药研发股份有限公司 |
作为 irak4 抑制剂的稠环化合物
|
|
JP7114394B2
(ja)
*
|
2017-08-18 |
2022-08-08 |
住友化学株式会社 |
化合物、レジスト組成物及びレジストパターンの製造方法
|
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
JP7366031B2
(ja)
|
2017-09-22 |
2023-10-20 |
カイメラ セラピューティクス， インコーポレイテッド |
タンパク質分解剤およびそれらの使用
|
|
PL3704108T3
(pl)
|
2017-10-31 |
2024-07-22 |
Curis, Inc. |
Inhibitor irak4 w połączeniu z inhibitorem bcl-2 do stosowania w leczeniu nowotworu złośliwego
|
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
CA3084074C
(en)
*
|
2017-11-30 |
2023-03-21 |
Hanmi Pharm. Co., Ltd. |
THIENO[3,2-d]PYRIMIDINE COMPOUND HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
CN112236429B
(zh)
*
|
2018-04-05 |
2024-10-11 |
默克专利有限公司 |
用作ii型irak抑制剂的杂芳基化合物及其用途
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
TWI721483B
(zh)
|
2018-07-13 |
2021-03-11 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
CN110862375B
(zh)
*
|
2018-08-27 |
2022-10-25 |
深圳铂立健医药有限公司 |
吡唑化合物及其药物组合物和应用
|
|
CR20210202A
(es)
|
2018-10-30 |
2022-02-08 |
Kronos Bio Inc |
Compuestos, composiciones y métodos para modular la actividad cdk9
|
|
PH12021500026A1
(en)
|
2018-11-30 |
2022-05-11 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
MX2021015498A
(es)
*
|
2019-06-27 |
2022-04-20 |
Biogen Ma Inc |
Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades.
|
|
WO2021066559A1
(en)
|
2019-10-02 |
2021-04-08 |
Kainos Medicine, Inc. |
N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
|
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
EP4076520A4
(en)
|
2019-12-17 |
2024-03-27 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADATION AGENTS AND THEIR USES
|
|
EP4125900A1
(en)
|
2020-04-04 |
2023-02-08 |
Pfizer Inc. |
Methods of treating coronavirus disease 2019
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
WO2022070289A1
(ja)
*
|
2020-09-30 |
2022-04-07 |
旭化成ファーマ株式会社 |
ピリミジン含有含窒素二環化合物
|
|
US11866405B2
(en)
|
2020-12-10 |
2024-01-09 |
Astrazeneca Ab |
Substituted indazoles as IRAK4 inhibitors
|
|
KR20230143632A
(ko)
|
2020-12-30 |
2023-10-12 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
IL304907A
(en)
|
2021-02-15 |
2023-10-01 |
Kymera Therapeutics Inc |
Irak4 degraders and uses thereof
|
|
US11773103B2
(en)
|
2021-02-15 |
2023-10-03 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
|
AU2022254933A1
(en)
|
2021-04-08 |
2023-11-09 |
Curis, Inc. |
Combination therapies for the treatment of cancer
|
|
TW202309030A
(zh)
|
2021-05-07 |
2023-03-01 |
美商凱麥拉醫療公司 |
Cdk2降解劑及其用途
|
|
KR102869914B1
(ko)
*
|
2021-10-28 |
2025-10-13 |
재단법인 대구경북첨단의료산업진흥재단 |
신규한 티에노[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
|
|
EP4422635A4
(en)
|
2021-10-29 |
2025-11-26 |
Kymera Therapeutics Inc |
IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
|
|
EP4472967A2
(en)
|
2022-01-31 |
2024-12-11 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|